Literature DB >> 7012993

The pharmacokinetics of bacampicillin.

H C Neu.   

Abstract

Bacampicillin is an ethoxycarbonyloxyethyl ester of ampicillin that is rapidly converted to free ampicillin, the active agent, by nonspecific esterases present in serum and in the intestinal wall. The compound is absorbed more rapidly than ampicillin, with peak absorption occurring 45 min to 1 hr after administration of the drug, whereas the peak after administration of the parent compound is at 2 hr. Peak levels of drug in serum after a 400-mg dose of bacampicillin (molar equivalent, 278 mg of ampicillin) are 6-8 micrograms/ml. Peak levels after an 800-mg dose of bacampicillin (molar equivalent, 556 mg of ampicillin) are 11-14 micrograms/ml. These peak levels are twofold greater than those achieved with equimolar doses of ampicillin. Ingestion of bacampicillin with food does not decrease or delay absorption of the drug. Recovery of ampicillin in urine after ingestion of bacampicillin is 75% vs. a recovery of 45% after ampicillin. Ampicillin appears earlier in tears, saliva, bronchial and maxillary sinus secretions, middle ear fluid, skin blisters. lymph, and urethral and cervical secretions, and the levels obtained in these tissues are greater after ingestion of bacampicillin than after ampicillin. The pharmacokinetics of bacampicillin and ampicillin in the period 2.5-8 hr after their ingestion is virtually identical at equimolar doses.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7012993     DOI: 10.1093/clinids/3.1.110

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  5 in total

1.  Pharmacokinetic study of lenampicillin (KBT-1585) in healthy volunteers.

Authors:  A Saito; M Nakashima
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

Review 2.  Pharmacokinetics of bacampicillin tablets in adults.

Authors:  W A Craig
Journal:  Bull N Y Acad Med       Date:  1983-06

3.  Sequential parenteral oral antibiotic therapy for serious infections.

Authors:  J D Nelson
Journal:  Bull N Y Acad Med       Date:  1983-06

4.  Bacampicillin treatment of pneumococcal pneumonia in high risk patients.

Authors:  S Campbell
Journal:  Bull N Y Acad Med       Date:  1983-06

5.  Antibiotic tissue penetration.

Authors:  B A Cunha
Journal:  Bull N Y Acad Med       Date:  1983-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.